EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

Francesco Cappelli iD, Marianna Fontana, Pablo Garcia-Pavia iD, Daniel P Judge, Laura Obici iD, Ahmad Masri iD, Kai Vogtländer, Antonio Ciaccia, Ana Zazula iD, Jean-François Tamby, Adam Castaño, Jonathan C Fox und 4 weitere

European Journal of Heart Failure · 2026

DOI: 10.1093/ejhf/xuag048 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2026. Verfasst von Francesco Cappelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Tuscan Regional Amyloidosis Centre, Department of Clinical and Experimental Medicine, Careggi University Hospital, Largo Brambilla, 3, Florence, Ital…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Peptide Fragments, Cardiomyopathies, Prealbumin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BridgeBio Pharma Inc., San Francisco, CA, USA, Bayer AG, Berlin, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Acoramidis is an oral transthyretin (TTR) stabilizer that achieves near-complete (≥90%) TTR stabilization. This post-hoc analysis evaluated response categories based on NT-proBNP concentration and 6-minute walk distance (6MWD) changes among participants with transthyretin amyloid cardiomyopathy (ATTR-CM) in the phase 3 ATTRibute-CM trial.

Methods

Clinically meaningful improvement (CMI) was defined as a decrease from baseline to Month 30 in NT-proBNP of >700 ng/L and >30%, and separately, a 6MWD increase of >35 m.

Results

Data from 611 participants were analysed (409: acoramidis; 202: placebo). Median baseline NT-proBNP and 6MWD values were 2273 ng/L and 365 m in the acoramidis group and 2274 ng/L and 352 m in the placebo group, respectively. A significantly higher proportion of participants in the acoramidis group reached CMI in NT-proBNP or 6MWD (22.7%) compared with the placebo group (8.9%; OR 3.0, 95% CI 1.8–5.1; P < .001).

Conclusion

Acoramidis led to CMI from baseline in NT-proBNP concentration or 6MWD in a considerable proportion of participants with ATTR-CM. These findings suggest that the treatment paradigm of ATTR-CM may evolve from slowing disease progression to achieving improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialPeptide FragmentsCardiomyopathiesPrealbuminNatriuretic Peptide, BrainHumansFemaleMaleAgedWalk TestTreatment OutcomeDouble-Blind MethodPyrazolesBenzoic Acid

Stichwörter der Autor:innen

AcoramidisClinically meaningful improvementFunctional assessmentFunctional biomarkerPrognostic factorTransthyretin amyloid cardiomyopathy

Substanzen

Peptide FragmentsPrealbuminpro-brain natriuretic peptide (1-76)Natriuretic Peptide, BrainacoramidisPyrazolesBenzoic Acid

Autor:innen und Institutionen

  • Tuscan Regional Amyloidosis Centre, Department of Clinical and Experimental Medicine, Careggi University Hospital, Largo Brambilla, 3, Florence, Italy, 50134.
  • National Amyloidosis Centre, University College London, London, UK.
  • Department of Cardiology of Hospital Universitario Puerta de Hierro Majadahonda, Instituto Investigación Sanitaria Puerta de Hierro, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares and Centro Naci…
  • Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University, Portland, OR, USA.

ORCID-Profile: Francesco Cappelli, Pablo Garcia-Pavia, Laura Obici, Ahmad Masri, Ana Zazula, Thibaud Damy

Förderung

  • BridgeBio Pharma Inc., San Francisco, CA, USA
  • Bayer AG, Berlin, Germany

Zitieren

APA

Cappelli, F., Fontana, M., Garcia-Pavia, P., Judge, D. P., Obici, L., Masri, A., Vogtländer, K., Ciaccia, A., Zazula, A., Tamby, J. F., Castaño, A., Fox, J. C., Poulsen, S. H., Damy, T., Januzzi, J. L., & Gillmore, J. D. (2026). Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM. European Journal of Heart Failure. https://doi.org/10.1093/ejhf/xuag048

Vancouver

Cappelli F, Fontana M, Garcia-Pavia P, Judge DP, Obici L, Masri A, et al. Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM. European Journal of Heart Failure. 2026. doi:10.1093/ejhf/xuag048

BibTeX
@article{Cappelli2026,
  author = {Cappelli, Francesco and Fontana, Marianna and Garcia-Pavia, Pablo and Judge, Daniel P and Obici, Laura and Masri, Ahmad and Vogtländer, Kai and Ciaccia, Antonio and Zazula, Ana and Tamby, Jean-François and Castaño, Adam and Fox, Jonathan C and Poulsen, Steen H and Damy, Thibaud and Januzzi, James L and Gillmore, Julian D},
  title = {Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM},
  journal = {European Journal of Heart Failure},
  year = {2026},
  doi = {10.1093/ejhf/xuag048}
}
Kostenlos starten →